1035572-38-3 Usage
Functional Groups
Chloropyridinyl: Present at position 4 of the pyridine ring, contributes to potential pharmacological properties.
Acetyl: Attached to the pyridine ring, suggests possible interactions with metabolic enzymes.
Dimethoxyphenoxy: Linked to position 6 of the pyridine ring, provides structural complexity and potential reactivity.
Propylacetamide: Attached to the nitrogen atom, may participate in interactions with biological receptors.
Pharmaceutical Potential
Structural Features: Enable potential interactions with specific receptors or enzymes.
Acetyl Group: Suggests involvement in metabolic pathways.
Propylacetamide Group: Indicates potential binding affinity with biological targets.
Chloropyridinyl Group: May confer specific pharmacological properties.
Implications
Drug Discovery: Represents a candidate for further investigation in pharmaceutical research.
Development: Holds promise for the development of novel therapeutic agents.
Check Digit Verification of cas no
The CAS Registry Mumber 1035572-38-3 includes 10 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 7 digits, 1,0,3,5,5,7 and 2 respectively; the second part has 2 digits, 3 and 8 respectively.
Calculate Digit Verification of CAS Registry Number 1035572-38:
(9*1)+(8*0)+(7*3)+(6*5)+(5*5)+(4*7)+(3*2)+(2*3)+(1*8)=133
133 % 10 = 3
So 1035572-38-3 is a valid CAS Registry Number.
1035572-38-3Relevant articles and documents
Discovery and early clinical development of 2-{6-[2-(3,5-dichloro-4- pyridyl)acetyl]-2,3-dimethoxyphenoxy}- N -propylacetamide (LEO 29102), a soft-drug inhibitor of phosphodiesterase 4 for topical treatment of atopic dermatitis
Felding, Jakob,S?rensen, Morten D.,Poulsen, Tina D.,Larsen, Jens,Andersson, Christina,Refer, Pia,Engell, Karen,Ladefoged, Lotte G.,Thormann, Thorsten,Vinggaard, Anne Marie,Hegardt, Pontus,S?hoel, Anders,Nielsen, Simon Feldb?k
, p. 5893 - 5903 (2014/08/18)
Development of orally available phosphodiesterase 4 (PDE4) inhibitors as anti-inflammatory drugs has been going on for decades. However, only roflumilast has received FDA approval. One key challenge has been the low therapeutic window observed in the clin
SUBSTITUTED ACETOPHENONES USEFUL AS PDE4 INHIBITORS
-
Page/Page column 71, (2008/12/06)
The present invention relates to a compound according to formula: (I); wherein X1, X2, X3, X4 and X5 independently of each other represent -CH- or N; or X3, X4 and X5
